Evaluation Of Bax Encoding Plasmid For Increasing Efficacy Of DNA Vaccine Plasmid Encoding GB Of Herpes Simplex Virus Type 1

Document Type : Original Article


1 Virology Department, School of Medical Sciences, Tarbiat Modarres University

2 Immunology Department, Faculty of Medical Sciences, Tarbiat Modarres University

3 Iranian Blood Transfusion Organization, Research Center

4 Institute of Biochemistry and Biophysics, University of Tehran


Objective: Evaluation of Bax encoding plasmid for increasing efficacy of DNA vaccine plasmid encoding gB of Herpes Simplex Virus type 1.
Materials and Methods: We compared three different dosages of Bax encoding plasmid (pcbax) including 10, 25 and 50 μg of plasmid DNA. They were co-injected ineradermally with glycoprotein B (gB) of herpes simplex virus (HSV)-1 encoded plasmid (pcgB) in C57BL/6 mice to elicit immune responses to protect against lethal HSV-1 challenge. Immune responses to the antigen were assessed by lymphocyte proliferative responses and cytokine (INF-γ and IL-4) release assays.
Results: The study demonstrates that the mice immunized with 25 μg pcbax together with pcgB have more efficient protection than the mice immunized with 10 and 50 μg of pcbax and pcgB. Analysing of cell-mediated responses show that the mice immunized with 25μg pcbax and pcgB induce stronger lymphocyte proliferative responses and higher levels of INF-γ and IL-4 compared to the mice are received 10 and 50 μg of pcbax and pcgB.
Conclusion: The data show that co-immunization with 25 μg of pcbax and pcgB increase immune responses compared to 10 and 50 μg of pcbax and pcgB. This can be considered a promising approach for development an efficient DNA vaccine against HSV-1 or other pathogens.